


Implications of the NAS Report depend on how the program is implemented


International Implications of the NAS Report: Challenges and Opportunities

Ottawa, CA

June 29, 2009

Comments following Keynote
Melvin Andersen, PhD
The Hamner Institutes






Toxicity Testing in the 21st Century

... a not-so-distant future where all routine toxicity testing will be conducted in human cells or cell lines *in vitro* by evaluating perturbations of cellular responses in a suite of toxicity pathway assays.

Andersen and Krewski (2009). Toxicity Testing in the 21st Century: Bringing the Vision to Life. *Tox. Sci.*, 107, 324-330.

In the report (Figure 5-1) implementation as a linear, comprehensive overhaul plan -but




Moves to the mainstream after all steps are in place – maybe 20 years
Risk Assessment approaches only vaguely identified

An Alternative – Parallel topics Approach



- **Phase I:** Select a series of prototype compounds/pathways whose targets are well-understood; use these to cover key technology areas – assay design, computational/dose response modeling, in vitro-in vivo extrapolation, etc.; **show how the process works for risk/safety assessment; compare to current methods;** make mid-course corrections.
- **Phase II:** Extend quickly to other materials and expand assays evaluated in current high throughput projects – giving more attention to assay design and pathway validation.
- Formalize process and approaches for using the information for safety/risk assessment

Understanding Toxicity Pathway Function/Design to guide assay design and dose response tools

Perturbations to Cellular Responses




Generic Controller Structure and Dose Response



Similar considerations for receptor mediated perturbations

X, e.g. (E2-ER)₂, Dioxin-AhR-ARNT, PPAR- α -PFOA-RXR, etc.




dose



Genes Y1- Y4

Genes Z1- Z3



Depicts a series of genes in a **network** – Y_i and Z_i - with aspects their dose relationships to the right

Toxicity Pathway Results and Quantitative Safety/Risk Assessments – The alternative

Use prototypes, with rich data sets, that affect specific pathway targets.

I. *in vitro* rapidly performed toxicity pathway test battery for n -assays in human cells, cell lines, or tissue aggregates


ii. Computational systems biology description of pathway circuitry for creating biologically realistic dose response models

Develop tools and models for pathway analysis and application in risk assessment

iii. Dose dependent transition studies for sequential pathway activation to understand linkage to cell and tissue level responses (perturbations to adversity)

Refine as we move along with examples.

iv. PBPK Modules – for *in vitro-in vivo* extrapolation, and inferring human population exposures for specific use patterns



Do representative risk/safety assessments

Can a transition be accomplished in a reasonable timeframe? How?

- Need a clearly articulated plan to move new methods into practice while moving away from present, animal-intensive approaches
- Do sequentially in the beginning for well-defined pathways with well-studied prototype compounds
- Process has to be defined with sufficient clarity about implementation to have a sense of the implications